Company Overview and News
KUALA LUMPUR (June 13): The FBM KLCI pared some of its loss at the midday break today and was down 0.25%, dragged by select blue chips.
PBLOF 7113 5253 BATS TPGVF 4162 AMMHF 1295 7153 2089 7077 5226 1201 PNAGF SPMXF UPBMF 7087 6033 TGLVY PNADF 4588 1015 SPMXY 5819 BSMAF 3719 1818
KUALA LUMPUR (June 13): Sumatec Resources Bhd shares rose 11.11% this morning after the company said it is confident that it will be declassified as a Practice Note 17 (PN17) company by 2019, as it looks to submit its regularisation plan to Bursa Malaysia "very soon".
1201 BSMAF 1818
KUALA LUMPUR (June 13): The FBM KLCI fell 0.41% at mid-morning today, tracking losses at regional markets, weighed by select index-linked blue chips.
HLFBF 7293 PBLOF SPMXF 1082 7113 TPGVF BATS 4162 1295 7077 6033 TGLVY PNADF SPMXY 5226 1201 2836 BSMAF PNAGF 1818
KUALA LUMPUR (June 13): The FBM KLCI is likely to struggle to make any gains today, as investors may take a wait and see approach until after the Hari Raya Aidilfitri holidays starting Friday.
5080 3204 1201 7079
KUALA LUMPUR (June 12): Sumatec Resources Bhd has been ordered to pay Continental Industrial Supplies and Services Ltd LLP, its claim balance of US$4.92 million (RM19.66 million).
KUALA LUMPUR (June 12): Based on corporate announcements and news flow today, companies in focus on Wednesday (June 13) may include: Bermaz Auto Bhd, Poh Kong Holdings Bhd, Tiger Synergy Bhd, Comintel Corp Bhd, PUC Bhd, AppAsia Bhd, Sumatec Resources Bhd and George Kent (M) Bhd.
5080 3204 1201 BSMAF 1818 7079
KUALA LUMPUR (June 12): Sumatec Resources Bhd is confident that it will be declassified as a Practice Note 17 (PN17) company by 2019, as it looks to submit its regularisation plan to Bursa Malaysia "very soon".
1201 BSMAF 1818
The world will be watching two of the greatest shows this week — the momentous meeting between US President Donald Trump and North Korean leader Kim Jong-un at the Capella Hotel in Singapore on June 12, and the kick-off of the 2018 Fifa World Cup in Moscow on Thursday, just ahead of the Hari Raya celebrations on Friday.
9717 5216 1201 3921 0091 CPICQ FUTR 5085 0151 8311 0152 LIIHF
SHARES of Sumatec Resources Bhd took a beating this week, plunging over 30% after external auditor Grant Thornton Malaysia cast doubt on the oil and gas (O&G) firm’s ability to continue as a going concern – turning it into a Practice Note 17 (PN17) company.
1201 BSMAF 1818
KUALA LUMPUR: Sumatec Resources Bhd plunged 30% after its external auditors expressed disclaimer opinion on its financial year ended Dec 31, 2017 (FY17) accounts.
PETALING JAYA: In levels not seen since December 2014, Brent crude oil hit US$71.72 as political tensions rose after US President Donald Trump’s tweet that he would fire missiles at Syria in response to a suspected chemical weapon attack.
1201 RDS.B RDS.A BRDBF XOM RYDBF RDSB RDSA RYDAF HIPEF 5199 5210
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...